In a pivotal reversal of roles, Pharmacopeia Drug Discovery (PDD) has exclusively licensed from global giant Bristol-Myers Squibb (BMS) preclinical compounds arising from a BMS discovery programme. Small molecules from this programme were generated to possess dual angiotensin (AT1) and endothelin (ETA) receptor antagonist activity in a single compound. This class of compounds is referred to as dual-acting receptor antagonists (DARAs). The DARA programme has become available because BMS is streamlining its product portfolio as part of its strategic realignment to focus on ten disease areas. The agreement also assists in PDD's strategic aim to mature into a clinical development company.